23 Recruiting Renal Cell Carcinoma Phase 2 Clinical Trials
Active phase 2 studies for renal cell carcinoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Renal Cell Carcinoma studiesPhase 2 Studies for Renal Cell Carcinoma
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
📍 UT Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔Follow-up After Metastasectomy in Patients With Kidney Cancer
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
📍 Johns Hopkins — Baltimore, Maryland
View Study & Checklist ➔Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
📍 Duke Cancer Institute — Durham, North Carolina
View Study & Checklist ➔Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
📍 Baylor College of Medicine — Houston, Texas
View Study & Checklist ➔Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
📍 Portland Providence Medical Center — Portland, Oregon
View Study & Checklist ➔Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
📍 City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) — Duarte, California
View Study & Checklist ➔Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
📍 Georgetown University Medical Center ( Site 1002) — Washington D.C., District of Columbia
View Study & Checklist ➔177LuPSMA in Renal Cell Carcinoma
📍 Brigham and Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔High Dose IL 2 and Entinostat in RCC
📍 Univeristy of Southern California — Los Angeles, California
View Study & Checklist ➔Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
📍 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
View Study & Checklist ➔Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites) — Basking Ridge, New Jersey
View Study & Checklist ➔Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
📍 UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
View Study & Checklist ➔Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
📍 UCSF Medical Center at Mission Bay ( Site 5008) — San Francisco, California
View Study & Checklist ➔Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
📍 City of Hope — Irvine, California
View Study & Checklist ➔Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
📍 Sibley Memorial Hospital — Washington D.C., District of Columbia
View Study & Checklist ➔Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
📍 Yale University — New Haven, Connecticut
View Study & Checklist ➔